Acute Pain – Pipeline Review, H1 2016

$2,000

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history ….

Total Pages: 202

Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H1 2016’, provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
- The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Pain Overview 10
Therapeutics Development 11
Pipeline Products for Acute Pain - Overview 11
Pipeline Products for Acute Pain - Comparative Analysis 12
Acute Pain - Therapeutics under Development by Companies 13
Acute Pain - Therapeutics under Investigation by Universities/Institutes 17
Acute Pain - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Acute Pain - Products under Development by Companies 22
Acute Pain - Products under Investigation by Universities/Institutes 26
Acute Pain - Companies Involved in Therapeutics Development 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
AcelRx Pharmaceuticals, Inc. 28
Adynxx, Inc. 29
Amorsa Therapeutics Inc. 30
AnaBios Corporation 31
Anavex Life Sciences Corp. 32
AngioChem Inc. 33
Antibe Therapeutics, Inc. 34
AskAt Inc. 35
Cara Therapeutics, Inc. 36
Centrexion Corporation 37
Charleston Laboratories, Inc. 38
ChironWells GmbH 39
Cytogel Pharma, LLC 40
Dompe Farmaceutici S.p.A. 41
Grunenthal GmbH 42
Iroko Pharmaceuticals, LLC 43
KemPharm, Inc. 44
Kineta, Inc. 45
Laboratorios Del Dr. Esteve S.A. 46
Mallinckrodt Plc 47
MEDRx Co., Ltd. 48
Nanomerics Ltd 49
Nanotherapeutics, Inc. 50
Nektar Therapeutics 51
Nuvo Research Inc. 52
Orbis Biosciences, Inc. 53
Orexo AB 54
Orion Oyj 55
Pacira Pharmaceuticals, Inc. 56
Phosphagenics Limited 57
Recro Pharma, Inc. 58
Shulov Innovative Science Ltd. 59
Sigma-Tau S.p.A. 60
Syntrix Biosystems, Inc. 61
Thar Pharmaceuticals, Inc. 62
Tonix Pharmaceuticals Holding Corp. 63
Trevena, Inc. 64
Yungjin Pharm. Co., Ltd. 65
Acute Pain - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 71
Assessment by Route of Administration 74
Assessment by Molecule Type 76
Drug Profiles 78
(acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile 78
(acetaminophen + hydrocodone bitartarate) ER - Drug Profile 80
(acetaminophen + tramadol hydrochloride) SR - Drug Profile 81
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 82
(celecoxib + tramadol hydrochloride) - Drug Profile 83
(dexketoprofen + tramadol hydrochloride) - Drug Profile 84
(etodolac + lidocaine) - Drug Profile 85
AAT-076 - Drug Profile 87
alfentanil hydrochloride - Drug Profile 88
AMS-410 FA - Drug Profile 89
ANAVEX-1037 - Drug Profile 90
ANAVEX-1066 - Drug Profile 91
ANAVEX-1067 - Drug Profile 92
ANAVEX-1079 - Drug Profile 93
ANAVEX-1519 - Drug Profile 94
ANG-2002 - Drug Profile 95
ARX-04 - Drug Profile 96
ATB-352 - Drug Profile 98
AYX-1 - Drug Profile 99
BBI-11008 - Drug Profile 100
celecoxib - Drug Profile 101
CL-108 - Drug Profile 102
CLH-10 - Drug Profile 103
CLH-5 - Drug Profile 104
CR-4056 - Drug Profile 105
CR-845 - Drug Profile 106
Cyt-1010 - Drug Profile 109
dexisometheptene mucate - Drug Profile 111
dexmedetomidine hydrochloride - Drug Profile 112
DF-2593A - Drug Profile 114
E-52862 - Drug Profile 115
ECP-1014 - Drug Profile 117
ET-1 - Drug Profile 118
FY-101C - Drug Profile 119
FY-103B - Drug Profile 120
grapiprant - Drug Profile 121
HS-731 - Drug Profile 123
ibuprofen - Drug Profile 124
ibuprofen - Drug Profile 125
ibuprofen - Drug Profile 126
ketamine hydrochloride - Drug Profile 127
lidocaine hydrochloride - Drug Profile 129
meloxicam - Drug Profile 130
meloxicam ER - Drug Profile 131
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 132
NKTR-195 - Drug Profile 133
NM-0127 - Drug Profile 134
oliceridine - Drug Profile 135
Omnitram - Drug Profile 136
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 137
prednisone - Drug Profile 138
Prostatic Acid Phosphatase - Drug Profile 139
RO-656570 - Drug Profile 140
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 141
Small Molecules to Block Nav 1.7 for Pain - Drug Profile 142
Small Molecules to Block Nav 1.8 for Pain - Drug Profile 143
ST-4070 - Drug Profile 144
T-109 - Drug Profile 145
tapentadol hydrochloride IR - Drug Profile 146
TRV-734 - Drug Profile 148
U-2902 - Drug Profile 149
VPX-595 - Drug Profile 151
ZEP-3 - Drug Profile 152
Acute Pain - Recent Pipeline Updates 154
Acute Pain - Dormant Projects 184
Acute Pain - Discontinued Products 190
Acute Pain - Product Development Milestones 191
Featured News & Press Releases 191
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables
Number of Products under Development for Acute Pain, H1 2016 15
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2016 21
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Development, H1 2016 24
Comparative Analysis by Unknown Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2016 30
Acute Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 31
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2016 32
Acute Pain - Pipeline by Adynxx, Inc., H1 2016 33
Acute Pain - Pipeline by Amorsa Therapeutics Inc., H1 2016 34
Acute Pain - Pipeline by AnaBios Corporation, H1 2016 35
Acute Pain - Pipeline by Anavex Life Sciences Corp., H1 2016 36
Acute Pain - Pipeline by AngioChem Inc., H1 2016 37
Acute Pain - Pipeline by Antibe Therapeutics, Inc., H1 2016 38
Acute Pain - Pipeline by AskAt Inc., H1 2016 39
Acute Pain - Pipeline by Cara Therapeutics, Inc., H1 2016 40
Acute Pain - Pipeline by Centrexion Corporation, H1 2016 41
Acute Pain - Pipeline by Charleston Laboratories, Inc., H1 2016 42
Acute Pain - Pipeline by ChironWells GmbH, H1 2016 43
Acute Pain - Pipeline by Cytogel Pharma, LLC, H1 2016 44
Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 45
Acute Pain - Pipeline by Grunenthal GmbH, H1 2016 46
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H1 2016 47
Acute Pain - Pipeline by KemPharm, Inc., H1 2016 48
Acute Pain - Pipeline by Kineta, Inc., H1 2016 49
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 50
Acute Pain - Pipeline by Mallinckrodt Plc, H1 2016 51
Acute Pain - Pipeline by MEDRx Co., Ltd., H1 2016 52
Acute Pain - Pipeline by Nanomerics Ltd, H1 2016 53
Acute Pain - Pipeline by Nanotherapeutics, Inc., H1 2016 54
Acute Pain - Pipeline by Nektar Therapeutics, H1 2016 55
Acute Pain - Pipeline by Nuvo Research Inc., H1 2016 56
Acute Pain - Pipeline by Orbis Biosciences, Inc., H1 2016 57
Acute Pain - Pipeline by Orexo AB, H1 2016 58
Acute Pain - Pipeline by Orion Oyj, H1 2016 59
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H1 2016 60
Acute Pain - Pipeline by Phosphagenics Limited, H1 2016 61
Acute Pain - Pipeline by Recro Pharma, Inc., H1 2016 62
Acute Pain - Pipeline by Shulov Innovative Science Ltd., H1 2016 63
Acute Pain - Pipeline by Sigma-Tau S.p.A., H1 2016 64
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H1 2016 65
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2016 66
Acute Pain - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 67
Acute Pain - Pipeline by Trevena, Inc., H1 2016 68
Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 69
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Stage and Target, H1 2016 73
Number of Products by Stage and Mechanism of Action, H1 2016 76
Number of Products by Stage and Route of Administration, H1 2016 79
Number of Products by Stage and Molecule Type, H1 2016 81
Acute Pain Therapeutics - Recent Pipeline Updates, H1 2016 158
Acute Pain - Dormant Projects, H1 2016 188
Acute Pain - Dormant Projects (Contd..1), H1 2016 189
Acute Pain - Dormant Projects (Contd..2), H1 2016 190
Acute Pain - Dormant Projects (Contd..3), H1 2016 191
Acute Pain - Dormant Projects (Contd..4), H1 2016 192
Acute Pain - Dormant Projects (Contd..5), H1 2016 193
Acute Pain - Discontinued Products, H1 2016 194

List of Figures
Number of Products under Development for Acute Pain, H1 2016 15
Number of Products under Development for Acute Pain - Comparative Analysis, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 22
Comparative Analysis by Clinical Stage Development, H1 2016 23
Comparative Analysis by Early Stage Products, H1 2016 24
Assessment by Monotherapy Products, H1 2016 70
Assessment by Combination Products, H1 2016 71
Number of Products by Top 10 Targets, H1 2016 72
Number of Products by Stage and Top 10 Targets, H1 2016 72
Number of Products by Top 10 Mechanism of Actions, H1 2016 75
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 75
Number of Products by Top 10 Routes of Administration, H1 2016 78
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 78
Number of Products by Molecule Types, H1 2016 80
Number of Products by Stage and Molecule Types, H1 2016 80


LICENSE TYPE